Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108106 | 1.00 | TSHR (0.33) | TSHRCA1TRPV1TRPA1LMNA | |
| SCHEMBL16139789 | 1.00 | TSHR (0.33) | TSHRCA1TRPV1TRPA1LMNA | |
| SCHEMBL5186832 | 0.89 | ALDH1A1 (0.39) | TSHRTRPV1TRPA1LMNATDP1 | |
| SCHEMBL620986 | 0.89 | ALDH1A1 (0.39) | TSHRTRPV1TRPA1LMNATDP1 | |
| SCHEMBL620985 | 0.89 | ALDH1A1 (0.39) | TSHRTRPV1TRPA1LMNATDP1 | |
| SCHEMBL620984 | 0.89 | ALDH1A1 (0.39) | TSHRTRPV1TRPA1LMNATDP1 | |
| SCHEMBL106523 | 0.86 | TSHR (0.38) | TSHRCA1TRPV1TRPA1LMNA | |
| SCHEMBL3761524 | 0.81 | LMNA (0.48) | TSHRCA1TRPV1TRPA1LMNA | |
| SCHEMBL8059255 | 0.81 | TRPV1 (0.31) | TSHRCA1TRPV1TRPA1 | |
| SCHEMBL15423494 | 0.81 | TRPV1 (0.48) | CA1TRPV1TRPA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708377-B2 | Analogues and derivatives of cephalotaxine and methods for making and using the compounds | OREGON STATE UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-20170304321-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2017-10-26 | — | — | US | disclosed |
| WO-2016057713-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160022701-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS INC (US) | 2016-01-28 | — | — | US | disclosed |
| US-20150158903-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2014160441-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022701-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CYP21A2, CYP24A1, HSD17B2 | TSHR 1554/4885CA1 1639/4885TRPV1 3915/4885 |
| US-20150158903-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CHRNB4, CHRNB3, MC2R | TSHR 448/4885CA1 1571/4885TRPV1 1307/4885 |
| US-11708377-B2 | Analogues and derivatives of cephalotaxine and methods for making and using the compounds | SLC6A2, NAPRT, SLC6A3 | TSHR 3377/4885CA1 1222/4885TRPV1 2082/4885 |
| US-20170304321-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | GRIN3B, GRIN2A, GRIN1 | TSHR 2830/4885CA1 2977/4885TRPV1 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.